Mitzi Nagarkatti to Inflammatory Bowel Diseases
This is a "connection" page, showing publications Mitzi Nagarkatti has written about Inflammatory Bowel Diseases.
Connection Strength
0.695
-
Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel. Nat Commun. 2022 01 26; 13(1):525.
Score: 0.187
-
Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016 Jan; 77:44-9.
Score: 0.122
-
The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol. 2014 Jan; 33(1):23-33.
Score: 0.104
-
Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol. 2012 Feb; 31(1):66-84.
Score: 0.094
-
Stem cells as potential therapeutic targets for inflammatory bowel disease. Front Biosci (Schol Ed). 2010 06 01; 2(3):993-1008.
Score: 0.084
-
Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis. PLoS One. 2018; 13(7):e0199631.
Score: 0.037
-
An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2018 08 01; 315(2):G220-G230.
Score: 0.036
-
Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation. Brain Behav Immun. 2017 Jan; 59:10-20.
Score: 0.032